39. Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease

  1. C. Warren Olanow MD, FRCPC1,2,3,
  2. Fabrizio Stocchi MD, PhD4 and
  3. Anthony E. Lang MD, FRCPC5,6,7
  1. C. Warren Olanow MD, FRCPC1,2,3 and
  2. Anthony E. Lang MD, FRCPC5,6,7

Published Online: 27 JUN 2011

DOI: 10.1002/9781444397970.ch39

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

How to Cite

Olanow, C. W. and Lang, A. E. (2011) Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease, in Parkinson's Disease: Non-Motor and Non-Dopaminergic Features (eds C. W. Olanow, F. Stocchi and A. E. Lang), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444397970.ch39

Editor Information

  1. 1

    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA

  2. 2

    Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA

  3. 3

    Robert and John M. Bendheim Parkinson's Disease Center, Mount Sinai School of Medicine, New York, NY, USA

  4. 4

    Parkinson's Disease and Movement Disorders Research Centre, Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy

  5. 5

    Division of Neurology, University of Toronto, Toronto, ON, Canada

  6. 6

    Parkinson's Disease Research, University of Toronto, Toronto, ON, Canada

  7. 7

    Movement Disorder Centre, Toronto Western Hospital, Toronto, ON, Canada

Author Information

  1. 1

    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA

  2. 2

    Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA

  3. 3

    Robert and John M. Bendheim Parkinson's Disease Center, Mount Sinai School of Medicine, New York, NY, USA

  4. 5

    Division of Neurology, University of Toronto, Toronto, ON, Canada

  5. 6

    Parkinson's Disease Research, University of Toronto, Toronto, ON, Canada

  6. 7

    Movement Disorder Centre, Toronto Western Hospital, Toronto, ON, Canada

Publication History

  1. Published Online: 27 JUN 2011
  2. Published Print: 29 JUL 2011

ISBN Information

Print ISBN: 9781405191852

Online ISBN: 9781444397970

SEARCH

Keywords:

  • neuroprotective therapies - modulating non-dopaminergic features in Parkinson's disease;
  • non-motor and nondopaminergic features of PD - need for effective therapies;
  • obstacles, to neuroprotective therapy - uncertainty, as to precise etiology;
  • protein accumulation, PD etiology - as Lewy bodies and Lewy neurites;
  • proteolytic stress, key factor in cell death in PD - and novel candidate targets;
  • outcome measures, and study designs - detecting disease-modification;
  • delayed-start study - information regarding mechanism;
  • neuroprotection trial, and populations studied - crucial;
  • disease-modifying therapy - disabling non-dopaminergic features, unmet need in PD;
  • new study designs - delayed-start and long-term simple study, promising

Summary

This chapter contains sections titled:

  • Introduction

  • Etiopathogenesis of PD

  • Animal models of PD

  • Outcome measures and study designs to detect disease-modification

  • Optimal population to study in disease-modifying trials

  • Conclusions

  • References